We are live on ! Find out more
CCM

Camber Capital Management Portfolio holdings

AUM $1.07B
1-Year Est. Return 8.19%
This Fund
S&P 500
This Quarter Est. Return
+31.07%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$1.97B
AUM Growth
+$63.5M
Cap. Flow
-$144M
Cap. Flow %
-7.35%
Top 10 Hldgs %
56.65%
Holding
39
New
5
Increased
6
Reduced
7
Closed
10

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$97.7M
2
VTR icon
Ventas
VTR
+$47.1M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$43.3M
4
MD icon
Pediatrix Medical
MD
+$19.8M
5
TEVA icon
Teva Pharmaceuticals
TEVA
+$17.9M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$76.1M
2
ABBV icon
AbbVie
ABBV
+$37.9M
3
ZYME icon
Zymeworks
ZYME
+$37.2M
4
NVO
Novo Nordisk
NVO
+$36.2M
5
DVA icon
DaVita
DVA
+$33.2M

Sector Composition

Rank Sector Weight
1 Healthcare 96.16%
2 Real Estate 2.2%
3 Miscellaneous 1.64%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AGN
1
DELISTED
Allergan plc
AGN
$191M 9.73%
1,000,000
– –
VTRS icon
2
Viatris
VTRS
$19.1B
$176M 8.95%
8,750,000
+250,000
+3% +$4.65M
BIIB icon
3
Biogen
BIIB
$31.9B
$104M 5.29%
350,000
– –
GILD icon
4
Gilead Sciences
GILD
$181B
$97.5M 4.96%
+1,500,000
New +$97.7M
THC icon
5
Tenet Healthcare
THC
$21B
$95.1M 4.84%
2,500,000
-650,000
-21% -$19.5M
ALXN
6
DELISTED
Alexion Pharmaceuticals
ALXN
$94.6M 4.82%
875,000
+25,000
+3% +$2.67M
ASND icon
7
Ascendis Pharma A/S
ASND
$15.8B
$92.2M 4.69%
663,000
+13,000
+2% +$1.44M
BKD icon
8
Brookdale Senior Living
BKD
$2.83B
$90.9M 4.62%
12,500,000
– –
PRGO icon
9
Perrigo
PRGO
$1.88B
$87.8M 4.47%
1,700,000
– –
ALKS icon
10
Alkermes
ALKS
$7.72B
$84.2M 4.28%
4,125,000
+625,000
+18% +$12.4M
NKTR icon
11
Nektar Therapeutics
NKTR
$2.28B
$80.9M 4.12%
250,000
+50,000
+25% +$14.5M
SRPT icon
12
Sarepta Therapeutics
SRPT
$2.19B
$77.4M 3.94%
600,000
-150,000
-20% -$15.1M
DVA icon
13
DaVita
DVA
$12.2B
$75M 3.82%
1,000,000
-500,000
-33% -$33.2M
UHS icon
14
Universal Health Services
UHS
$10.4B
$71.7M 3.65%
500,000
– –
THOR
15
DELISTED
Synthorx, Inc. Common Stock
THOR
$69.9M 3.56%
1,000,000
-862,116
-46% -$24.6M
MNTA
16
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$64.1M 3.26%
3,250,000
-250,000
-7% -$4M
HCA icon
17
HCA Healthcare
HCA
$91.8B
$59.1M 3.01%
400,000
-200,000
-33% -$26.9M
GBT
18
DELISTED
Global Blood Therapeutics, Inc.
GBT
$58M 2.95%
+730,000
New +$43.3M
AMAG
19
DELISTED
AMAG Pharmaceuticals
AMAG
$53.4M 2.72%
4,390,000
– –
ATRA icon
20
Atara Biotherapeutics
ATRA
$94.8M
$48.6M 2.47%
118,000
– –
VTR icon
21
Ventas
VTR
$45.4B
$43.3M 2.2%
+750,000
New +$47.1M
VTRS icon
22
CALL
Viatris
VTRS
$19.1B
$32.2M 1.64%
1,600,000
-1,400,000
-47% -$26.1M
MYGN icon
23
Myriad Genetics
MYGN
$371M
$27.2M 1.39%
1,000,000
– –
MD icon
24
Pediatrix Medical
MD
$2.17B
$22M 1.12%
+790,000
New +$19.8M
TEVA icon
25
Teva Pharmaceuticals
TEVA
$45.7B
$19.6M 1%
+2,000,000
New +$17.9M
1
2

Similar funds

PP
PrairieView Partners St. Paul, Minnesota $1.03B AUM 11.4% 1-Year Est. Return
SAF
Smith Anglin Financial Dallas, Texas $1.1B AUM 14.08% 1-Year Est. Return
NRD
Nebula Research & Development New York $1.17B AUM 15.19% 1-Year Est. Return
FC
Forte Capital Rochester, New York $930M AUM 24.11% 1-Year Est. Return
GIM
Grassi Investment Management Santa Clara, California $1.26B AUM 23.4% 1-Year Est. Return
SC
Savoie Capital Chicago, Illinois $805M AUM 19.48% 1-Year Est. Return
BWA
Bordeaux Wealth Advisors Menlo Park, California $781M AUM 26.55% 1-Year Est. Return
CCP
Camelot Capital Partners Laguna Beach, California $686M AUM 163.55% 1-Year Est. Return

Camber Capital Management's Q4 2019 Portfolio in Review

As of Q4 2019, Camber Capital Management held 39 positions worth $1.97B, up 3.3% from $1.9B the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Camber Capital Management withdrew a net $144M in Q4 2019, closing 10 positions and reducing 7 holdings. Its most notable exit was Bristol-Myers Squibb, an estimated $76.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 92% a quarter earlier, followed by Real Estate and Miscellaneous.

Against the trend, Camber Capital Management opened a new position in Gilead Sciences worth $97.5M.

  • Camber Capital Management's largest Q4 2019 buy was Gilead Sciences: 1,500,000 shares worth $97.5M.
  • Camber Capital Management added most to Nektar Therapeutics in Q4 2019, an estimated $14.5M increase.
  • Camber Capital Management's biggest Q4 2019 reduction was DaVita, cutting an estimated $33.2M.
  • Camber Capital Management fully exited Bristol-Myers Squibb in Q4 2019, selling an estimated $76.1M.
  • Camber Capital Management's ten largest holdings make up 57% of its $1.97B portfolio in Q4 2019.
  • Camber Capital Management opened 5 new positions and closed 10 in Q4 2019.
  • Camber Capital Management's portfolio value rose 3.3% quarter-over-quarter to $1.97B.

Based on Camber Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.